Form 4 Filing for C4 Therapeutics, Inc.

This filing details a Form 4 submitted by Stephen Fawell, a director at C4 Therapeutics, Inc. (CCCC). On June 24, 2026, Fawell was granted 62,000 stock options to purchase common stock, with an exercise price of $4.25 per share. These options are set to vest in full on June 24, 2027, or the next annual stockholder meeting, provided Fawell remains a board member. The options have an expiration date of June 23, 2036. This transaction is classified as an acquisition of stock options.